ZUG, SWITZERLAND -- Galderma will present six posters with the latest updates from its science-backed aesthetic portfolio at the Aesthetic & Anti-Aging Medicine World Congress (AMWC) in Dubai, United Arab Emirates, from October 1-3, 2025. The company will also showcase its leadership in aesthetic education through a number of events including a symposium and medical affairs session, and host Meet-the-Expert and interactive lab sessions led by expert community partners at its booth, B-145.

“Our presence at AMWC Dubai reflects Galderma’s commitment to being a true partner to the medical aesthetics community with the broadest Injectable Aesthetics portfolio, globally scaled commercial presence and leading training activities and services. Through events like these, we can engage directly with practitioners to stay closely attuned to their evolving needs. These learnings, combined with our innovations rooted in science, can help empower practitioners to deliver aesthetic outcomes that truly align with their patients’ needs.”

FLEMMING ØRNSKOV, M.D., MPH
CHIEF EXECUTIVE OFFICER
GALDERMA

Results reinforce the power of Restylane in personalized aesthetics

Galderma will present post-marketing data from the ARTIST study on its Restylane hyaluronic acid (HA) injectables portfolio, uniquely formulated to closely match and work in sync with the skin’s own HA for natural-looking results.[1], [6], [7] Data support the safety and effectiveness of the latest innovation in the portfolio - Restylane Shaype™ powered by new NASHA HD™ technology - when used alone in the chin region or in combination with Restylane Lyft™ for midface treatment and/or Restylane Defyne™ for soft transitions in the chin, known as The Shayping Technique.[1]

In all groups, both investigators and patients agreed that 100% of patients experienced aesthetic improvement at both four and eight weeks post-injection, as measured by the Global Aesthetic Improvement Scale.[1] Satisfaction with results was also high across all groups, with 100% of patients reporting improved chin definition and natural-looking results at Week eight.[1] In addition, investigators found that Restylane Shaype stayed where injected in all patients, while the injection site could be massaged and molded immediately after injection to achieve the desired results.[1] In addition, new insights highlighting the critical role of the ratio between enzyme volume and filler volume in achieving effective and predictable filler dissolution outcomes will be presented.[8]

Advancing Galderma’s pioneering efforts in regenerative aesthetics and addressing the aesthetic impact of medication-driven weight loss

Results from an expert consensus on Sculptra® - the first regenerative biostimulator - will be shared, strengthening understanding of its regenerative properties across all three skin layers.[3], [9-13] Sculptra’s effects were found to include fibroblast activation, which leads to stimulation of collagen, elastin and other proteins involved in extracellular matrix regeneration.[3] These effects can clinically present as long-term improvements in skin properties, restoration of volume and firmness, increased skin quality and thickness, and other benefits.[3] The expert panel concluded, based on collated molecular science data and literature, that Sculptra stimulates regenerative pathways and has a key role to play in the field of regenerative aesthetics.[3]

Three-month data on Sculptra reinforcing its synergistic effect with Restylane Lyft or Contour™* to address the aesthetic concerns of patients experiencing facial volume loss associated with medication-driven weight loss will also be presented by expert facial plastic surgeon, Dr. Michael Somenek, on Wednesday October 1 at 11 AM GST / 9 AM CEST in Al Ameera Ballroom 3.[2] Results show that the combined Sculptra and Restylane Lyft or Contour regimen demonstrated skin quality improvements beyond volumization, with Restylane Lyft significantly improving skin hydration and Sculptra significantly improving skin radiance and thickness.[2]

In response to this growing patient need, Galderma will host a symposium titled ‘Aesthetic Changes in Medication-Driven Weight Loss: The Algorithms’ on Thursday October 2 at 11 AM - 1 PM GST / 9 - 11 AM CEST in Baniyas Ballroom 1. Aesthetic experts Dr. Mohamed Alsufyani, Dr. Shadan Naji, Dr. Firas Hamdan, Dr. Daniel Coimbra, Dr. Alessandra Haddad and Dr. Michael Somenek will explore the effects medication-driven weight loss can have on the face and aesthetic approaches to address this, featuring live demonstrations. This is part of Galderma’s leading efforts to support the community in identifying and addressing the most predominant aesthetic concerns of patients who have experienced medication-driven weight loss, as outlined in Galderma’s recent report.

“The exponential rise in the use of prescription weight loss medications has prompted the medical aesthetics community to quickly adapt to understand the related aesthetic needs. This is why having a platform at AMWC Dubai is so important to enable us to share the latest insights on addressing the unique aesthetic concerns of these patients, such as data showing how the benefits of Sculptra and Restylane can work together to enhance skin quality and emotional wellbeing.”

MICHAEL SOMENEK, M.D.
FACIAL PLASTIC SURGEON
WASHINGTON DC, UNITED STATES

Data highlights high patient satisfaction with latest innovation in liquid neuromodulation

A poster on results from four studies in the phase III READY clinical trial program, evaluating Relfydess™ (RelabotulinumtoxinA) - the first and only ready-to-use liquid neuromodulator created with PEARLTM Technology- will be presented.[4], [14] More convenient, this innovation eliminates the need for reconstitution, streamlining clinical workflow and ensuring consistent dosing.[15]

When used for both frown lines and crow’s feet, combined results reinforce its onset of action as early as day one and prolonged duration of effect through six months.[4] Subjects also reported consistently high satisfaction, underscoring the potential of Relfydess to redefine patient expectations in neuromodulation.[4]

*Restylane Contour is known as Restylane Volyme™ in countries outside of the U.S.